Guggenheim Initiates Coverage on Metsera (NASDAQ:MTSR)

Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSRGet Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $56.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 105.81% from the company’s previous close.

Several other research analysts also recently commented on MTSR. Evercore ISI assumed coverage on shares of Metsera in a report on Tuesday. They set an “outperform” rating for the company. Bank of America began coverage on Metsera in a research report on Tuesday. They issued a “buy” rating and a $38.00 target price on the stock.

View Our Latest Analysis on Metsera

Metsera Stock Performance

MTSR stock opened at $27.21 on Tuesday. Metsera has a one year low of $25.06 and a one year high of $32.81.

About Metsera

(Get Free Report)

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Recommended Stories

Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.